ACH
GEVA

ArrowMark Colorado Holdings’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

ArrowMark Colorado Holdings’s Portfolio GEVA Stock Details GEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-161,970
Closed -$15.8M – 317
2015
Q1 		$15.8M Sell
161,970
-77,690
-32% -$8.23M 0.41% 79
2014
Q4 		$22.2M Buy
239,660
+18,491
+8% +$1.46M 0.57% 59
2014
Q3 		$15.2M Buy
221,169
+23,556
+12% +$1.69M 0.42% 79
2014
Q2 		$20.7M Buy
197,613
+86,057
+77% +$7.32M 0.59% 63
2014
Q1 		$9.26M Sell
111,556
-120,919
-52% -$11.2M 0.3% 118
2013
Q4 		$15M Buy
232,475
+131,125
+129% +$7.78M 0.47% 83
2013
Q3 		$6.42M Buy
101,350
+85,850
+554% +$4.23M 0.21% 140
2013
Q2 		$651K Buy
+15,500
New +$706K 0.18% 80

ArrowMark Colorado Holdings's GEVA Position: Q2 2015 in Review

ArrowMark Colorado Holdings sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q2 2015, closing a stake of 161,970 shares — an estimated $15.8M sold.

ArrowMark Colorado Holdings first reported a position in GEVA in Q2 2013 and held it in 8 quarters. The position peaked at $22.2M in Q4 2014. 0 funds tracked by Wall St. Rank hold GEVA as of Q2 2015.

  • ArrowMark Colorado Holdings reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q2 2015 after selling out during the quarter.
  • ArrowMark Colorado Holdings sold 161,970 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q2 2015, an estimated $15.8M.
  • ArrowMark Colorado Holdings first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q2 2013 and held it in 8 quarters.
  • ArrowMark Colorado Holdings's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $22.2M in Q4 2014.
  • 0 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q2 2015.

Based on ArrowMark Colorado Holdings's 13F filing for Q2 2015, filed 14 Aug 2015.